Ortin Laboratories Limited (ORTINLAB)의 가격은 얼마입니까?

Ortin Laboratories Limited (ORTINLAB)의 가격은 $0.2488447입니다.

Ortin Laboratories Limited (ORTINLAB)의 시가 총액은 무엇입니까?

Ortin Laboratories Limited (ORTINLAB)의 시가 총액은 $2.01M입니다.

Ortin Laboratories Limited (ORTINLAB) 영업이익률

Ortin Laboratories Limited, a pharmaceutical company established in Hyderabad, India, in 1986, is engaged in the manufacturing and commercialization of a diverse range of medicines, drugs, and chemical intermediates. The company provides a wide array of pharmaceutical formulations, presented as tablets, capsules, syrups, and dry powders. These products target various therapeutic domains such as metabolic diseases (e.g., anti-diabetics), allergic reactions, infections (including broad-spectrum antibiotics and antifungals like quinolones, penicillins, cephalosporins, macrolides, and antifungals), pain management and fever reduction (analgesics and antipyretics), cardiovascular ailments (anti-anginal and cardiovascular products), digestive system disorders (antacids and anti-ulcerants), neurological and psychiatric conditions (sedatives, tranquilizers, psychiatry products), and nutritional supplementation (like vitamins, calcium, iron, and protein supplements). Specialized offerings also include anti-retroviral, anti-arthritic, anti-helminthic, anti-spasmodic, gynaec, appetite stimulators, and chemotherapeutic preparations. In addition to finished pharmaceuticals, Ortin produces active pharmaceutical ingredient (API) intermediates for applications such as anti-retrovirals, anti-diabetics, pain and fever medications, antibiotics, antifungals, antacids, anti-malarials, and anti-ulcerants. Its manufacturing capabilities also extend to fine chemicals and Grignard/alkali metal compounds. The company offers specialized services covering process development and characterization, analytical research, assay development, and product characterization. It also contributes to diagnostics through the development of rapid flow kits, assays, and reagents. Ortin Laboratories undertakes long-term contracts for the production of intermediates and the creation of novel APIs. Moreover, it actively functions as a merchant exporter of its finished pharmaceutical products.

연도	영업이익률	변화
2026 (TTM)	-989.65%	208.87%
2024	-320.41%	-7,220.22%
2023	4.50%	15.98%
2022	3.88%	-66.98%
2021	11.75%	505.67%
2020	1.94%	-35.76%
2019	3.02%	-36.02%
2018	4.72%	95.85%
2017	2.41%	-31.34%
2016	3.51%	3.24%
2015	3.40%	14.48%
2014	2.97%	-5.71%
2013	3.15%	3.62%
2012	3.04%	-10.32%
2011	3.39%	-18.31%
2010	4.15%	24.62%
2009	3.33%	-35.09%
2008	5.13%	0.00%

연도

영업이익률

변화

2026 (TTM)

-989.65%

208.87%

2024

-320.41%

-7,220.22%

2023

4.50%

15.98%

2022

3.88%

-66.98%

2021

11.75%

505.67%

2020

1.94%

-35.76%

2019

3.02%

-36.02%

2018

4.72%

95.85%

2017

2.41%

-31.34%

2016

3.51%

3.24%

2015

3.40%

14.48%

2014

2.97%

-5.71%

2013

3.15%

3.62%

2012

3.04%

-10.32%

2011

3.39%

-18.31%

2010

4.15%

24.62%

2009

3.33%

-35.09%

2008

5.13%

0.00%

회사	영업이익률	영업이익률 차이	국가
MERCK Kommanditgesellschaft auf Aktien MER.SW	0.00%	-	DE
Merck KGaA MRK.DE	0.00%	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0.00%	-	JP
Galderma Group AG GALD.SW	0.00%	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	22.93%	-100.02%	IN

회사

영업이익률

영업이익률 차이

국가